At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 169 enrolled
Drug / intervention
D-cycloserine +2 moredrug
Likely dose
D-cycloserine 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
D-cycloserine Enhancement of Exposure in Social Phobia
In Brief
A Phase 3 clinical trial evaluating D-cycloserine, Cognitive behavioral therapy (CBT), and 1 other intervention for Social Anxiety Disorder. Completed, enrolled 169 participants across 1 site.
Detailed Summary
This study will assess the effectiveness of D-cycloserine combined with cognitive-behavior therapy in treating people with social anxiety disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSocial Anxiety Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2007
Enrollment StartDec 2007
Primary CompletionDec 2011
TodayJul 2026
First PostedAug 14, 2007
Enrollment StartDec 1, 2007
Primary CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 18.9 years ago
Interventions
D-cycloserinedrug
50 mg
Cognitive behavioral therapy (CBT)behavioral
CBT sessions aim to help participants become more comfortable with social situations.
Placebodrug
Same dosage as active pill